欧洲机构建议批准阿尔茨海默氏病的药物Lecanemab,推翻先前的决定。 European agency recommends approval for Alzheimer's drug lecanemab, reversing earlier decision.

欧洲医药局建议批准对无ApoE 4 基因或该基因副本的成人病人进行白血病治疗,即老年痴呆症早期治疗。 The European Medicines Agency (EMA) has recommended approval for lecanemab, a treatment for early Alzheimer's disease, for adult patients without or with one copy of the ApoE ε4 gene. 这一积极的建议扭转了早先的负面评估,如果欧盟委员会在67天内最后确定,将在欧盟提供这种药物。 This positive recommendation reverses an earlier negative assessment and, if finalized by the European Commission within 67 days, will make the drug available in the EU. Lecanemab已经在美国和其他几个国家获得批准。 Lecanemab is already approved in the U.S. and several other countries.